{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:30:23Z","timestamp":1777307423406,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":493,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.4103\/ijmm.ijmm_20_34","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T04:18:46Z","timestamp":1589775526000},"page":"478-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Comparative Assessment of Clinical, Pharmacological and Antimicrobial Profile of Novel Anti-methicillin-resistant Staphylococcus aureus Agent Levonadifloxacin: Therapeutic Role in Nosocomial and Community Infections"],"prefix":"10.1016","volume":"37","author":[{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoma Vinay","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barney","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthur","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasanth","family":"Nagvekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Victor","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.4103\/ijmm.IJMM_20_34_bib1","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/519474","article-title":"Microbiology of antibiotic resistance in Staphylococcus aureus","volume":"45","author":"Appelbaum","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib2","doi-asserted-by":"crossref","first-page":"e00355-19","DOI":"10.1128\/AAC.00355-19","article-title":"The Microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0901.020277","article-title":"Maintaining fluoroquinolone class efficacy: Review of influencing factors","volume":"9","author":"Scheld","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3855\/jidc.3105","article-title":"Fluoroquinolone resistant mechanisms in methicillin-resistant Staphylococcus aureus clinical isolates in Cairo, Egypt","volume":"7","author":"Hashem","year":"2013","journal-title":"J Infect Dev Ctries"},{"key":"10.4103\/ijmm.IJMM_20_34_bib5","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum Anti-MRSA benzoquinolizine quinolone agent: Review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.4103\/ijmm.IJMM_20_34_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","article-title":"Developments in glycopeptide antibiotics","volume":"4","author":"Blaskovich","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1039\/C6MD00585C","article-title":"A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics","volume":"8","author":"Sarkar","year":"2017","journal-title":"Medchemcomm"},{"key":"10.4103\/ijmm.IJMM_20_34_bib8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4161\/viru.26909","article-title":"Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"4","author":"Seah","year":"2013","journal-title":"Virulence"},{"key":"10.4103\/ijmm.IJMM_20_34_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fpubh.2014.00217","article-title":"Vancomycin revisited \u2013 60 years later","volume":"2","author":"Rubinstein","year":"2014","journal-title":"Front Public Health"},{"key":"10.4103\/ijmm.IJMM_20_34_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jmii.2011.11.006","article-title":"Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"45","author":"Yeh","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.4103\/ijmm.IJMM_20_34_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3889\/oamjms.2019.009","article-title":"Vancomycin MIC Distribution among methicillin-resistant Staphylococcus aureus. Is reduced vancomycin susceptibility related to MIC creep?","volume":"7","author":"Othman","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.4103\/ijmm.IJMM_20_34_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib13","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib15","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: A systematic review and meta-analysis","volume":"11","author":"Sinha Ray","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.4103\/ijmm.IJMM_20_34_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","article-title":"Therapeutic Monitoring of Vancomycin: A Revised Consensus Guideline","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacotherapy."},{"key":"10.4103\/ijmm.IJMM_20_34_bib17","first-page":"87","article-title":"Clinical update on linezolid in the treatment of Gram-positive bacterial infections","volume":"5","author":"Ager","year":"2012","journal-title":"Infect Drug Resist"},{"key":"10.4103\/ijmm.IJMM_20_34_bib18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_20_34_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijantimicag.2010.03.007","article-title":"Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections","volume":"36","author":"Traunm\u00fcller","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.4103\/ijmm.IJMM_20_34_bib20","first-page":"ii45","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib21","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.4103\/ijmm.IJMM_20_34_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijantimicag.2018.04.022","article-title":"Bacteriological relevance of linezolid vs. vancomycin in postoperative empirical treatment of osteoarticular infections: A retrospective single-center study","volume":"52","author":"Takoudju","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_20_34_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkm431","article-title":"Effect of severity of sepsis on tissue concentrations of linezolid","volume":"61","author":"Thallinger","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1086\/500265","article-title":"Successful treatment of staphylococcal toxic shock syndrome with linezolid: A case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics","volume":"42","author":"Stevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2009.09.013","article-title":"Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: Meta-analysis of randomised controlled trials","volume":"35","author":"Beibei","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_20_34_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1185\/03007990903454912","article-title":"Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis","volume":"26","author":"Bounthavong","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.4103\/ijmm.IJMM_20_34_bib27","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"key":"10.4103\/ijmm.IJMM_20_34_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CE.S33430","article-title":"An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): Place in therapy","volume":"7","author":"Watkins","year":"2012","journal-title":"Core Evid"},{"key":"10.4103\/ijmm.IJMM_20_34_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10096-019-03754-1","article-title":"Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients","volume":"39","author":"Cazavet","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: A dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_20_34_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: Efficacy of linezolid with or without carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib34","first-page":"e01715","article-title":"In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12866-014-0292-5","article-title":"Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China","volume":"14","author":"Tian","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.4103\/ijmm.IJMM_20_34_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1592\/phco.24.1.41.34802","article-title":"Daptomycin","volume":"24","author":"Tedesco","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.4103\/ijmm.IJMM_20_34_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11908-014-0429-6","article-title":"High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it","volume":"16","author":"Smith","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.4103\/ijmm.IJMM_20_34_bib38","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1128\/AAC.00738-06","article-title":"Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria","volume":"51","author":"Mortin","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib39","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","article-title":"The action mechanism of daptomycin","volume":"24","author":"Taylor","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.4103\/ijmm.IJMM_20_34_bib40","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib41","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement. CLSI Document. M100-S29","year":"2019"},{"key":"10.4103\/ijmm.IJMM_20_34_bib42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): Implications for therapy after vancomycin treatment failure","volume":"66","author":"Kelley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: Results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.4103\/ijmm.IJMM_20_34_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.4103\/ijmm.IJMM_20_34_bib45","first-page":"47","article-title":"Daptomycin: An evidence-based review of its role in the treatment of Gram-positive infections","volume":"9","author":"Gonzalez-Ruiz","year":"2016","journal-title":"Infect Drug Resist"},{"key":"10.4103\/ijmm.IJMM_20_34_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib47","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1128\/AAC.00973-06","article-title":"Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and\/or rifampin in human monocytes and in broth against Staphylococcus aureus","volume":"51","author":"Baltch","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib48","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib49","doi-asserted-by":"crossref","first-page":"E824","DOI":"10.3390\/jcm8060824","article-title":"Efficacy and safety of ceftaroline for the treatment of community-acquired pneumonia: A systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J Clin Med"},{"key":"10.4103\/ijmm.IJMM_20_34_bib50","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dky439","article-title":"Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections","volume":"74","author":"Das","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib52","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2014.11.016","article-title":"Ceftaroline: Clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA","volume":"81","author":"Stryjewski","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib54","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus Infections: A systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_34_bib55","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.01150-08","article-title":"In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types","volume":"53","author":"Bhagwat","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib56","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkz493","article-title":"In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18","volume":"75","author":"Appalaraju","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib57","unstructured":"N Maharaj, R Jha, Y Chugh, R Yeole, M Patel, N De Souza, et al. A Phase 1 study of Single Escalating Doses of Intravenous (IV) WCK 771. In Poster no A-21, 44th InterScience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington DC 2005."},{"key":"10.4103\/ijmm.IJMM_20_34_bib58","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1099\/jmm.0.001102","article-title":"Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations","volume":"68","author":"Dubois","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_20_34_bib59","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.4103\/ijmm.IJMM_20_34_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00084-20","article-title":"Levonadifloxacin, a novel benzoquinolizine fluoroquinolone modulates lipopolysaccharide induced inflammatory responses in human whole blood assay and murine acute lung injury model","author":"Patel","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_20_34_bib61","unstructured":"Mehrotra S, Ivaturi V, Gobburu J, Chugh R, Bhatia A. Pharmacokinetics of intravenous WCK 771 in healthy US adults. Abstract A-031, Presented at 55th ICAAC; 2015."},{"key":"10.4103\/ijmm.IJMM_20_34_bib62","doi-asserted-by":"crossref","first-page":"e00909","DOI":"10.1128\/AAC.00909-19","article-title":"In vivo pharmacokinetic\/pharmacodynamic targets of levonadifloxacin against Staphylococcus aureus in a neutropenic murine lung infection model","volume":"63","author":"Bhagwat","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720313293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720313293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:17:38Z","timestamp":1759346258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085720313293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0255085720313293"],"URL":"https:\/\/doi.org\/10.4103\/ijmm.ijmm_20_34","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparative Assessment of Clinical, Pharmacological and Antimicrobial Profile of Novel Anti-methicillin-resistant Staphylococcus aureus Agent Levonadifloxacin: Therapeutic Role in Nosocomial and Community Infections","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/ijmm.IJMM_20_34","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Indian Journal of Medical Microbiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}